

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (currently amended) A composition comprising a biologically effective amount of at least ~~a first~~ one tetraalkylammonium tetrathiomolybdate compound and a pharmaceutically acceptable excipient.
2. (currently amended) The composition of claim 1, wherein said ~~composition~~ comprises compound is tetramethylammonium tetrathiomolybdate.
3. (currently amended) The composition of claim 1, wherein said ~~composition~~ comprises compound is tetraethylammonium tetrathiomolybdate.
4. (currently amended) The composition of claim 1, wherein said ~~composition~~ comprises compound is tetrabutylammonium tetrathiomolybdate.
5. (currently amended) The composition of claim 1, wherein said ~~composition~~ comprises compound is tetrapropylammonium tetrathiomolybdate.
6. (currently amended) The composition of claim 1 or 5, wherein said composition is formulated for intravenous administration.
7. (currently amended) The composition of claim 1 or 5, wherein said composition is formulated for ophthalmic administration.
8. (currently amended) The composition of claim 1 or 5, wherein said composition is formulated for oral administration.
9. (currently amended) The composition of claim 1 or 5, further comprising at least a second, distinct therapeutic agent different from said tetraalkylammonium tetrathiomolybdate compound.
10. (original) The composition of claim 9, further comprising a zinc compound.

11. (currently amended) The composition of claim 9, ~~further comprising at least a second, distinct~~ wherein the therapeutic agent is an anti-angiogenic agent.

12. (currently amended) The composition of claim 11, ~~further comprising at least a~~ wherein the second anti-angiogenic agent is selected from the group consisting of angiostatin, endostatin, trientine, pencillamine, and zinc.

13. (currently amended) The composition of claim 9, ~~further comprising at least a second, distinct~~ wherein the therapeutic agent is an anti-cancer agent.

14. (currently amended) The composition of claim 13, ~~further comprising at least a~~ wherein the second anti-cancer agent is selected from the group consisting of a chemotherapeutic agent, radiotherapeutic agent, immunotoxin, anti-angiogenic agent, apoptosis-inducing agent, a distinct agent that binds copper, and a zinc compound.

15. (currently amended) A composition comprising a pharmaceutically acceptable excipient and a tetraalkylammonium tetrathiomolybdate compound in which the alkyl groups protect the tetrathiomolybdate from oxidation upon exposure to air and moisture, thereby increasing the stability of the tetraalkylammonium tetrathiomolybdate compound relative to ammonium tetrathiomolybdate; wherein said tetraalkylammonium tetrathiomolybdate compound retains solubility and releases substantially biologically active tetrathiomolybdate and substantially biologically inert alkylammonium groups in aqueous solution.

16. (currently amended) A composition comprising a biologically effective amount of a tetraalkylammonium tetrathiomolybdate compound and a pharmaceutically acceptable excipient; wherein said tetraalkylammonium tetrathiomolybdate compound is substantially stable in moist heated air for at least ~~about~~ 7 days; has a half life when exposed to air at room temperature of at least twice that of ammonium tetrathiomolybdate; is soluble to at least ~~about~~ 1 mg/ml in water; and in aqueous solution releases tetrathiomolybdate having substantially intact copper binding properties.

17. (original) A composition comprising a biologically effective amount of tetrapropylammonium tetrathiomolybdate and a pharmaceutically acceptable excipient.

18. (currently amended) A kit comprising, in at least ~~a first~~ one container, a therapeutically effective amount of at least ~~a first~~ one tetraalkylammonium tetrathiomolybdate compound and: (a) a therapeutically effective amount of at least a ~~second, distinct~~ therapeutic agent that is different from said tetraalkylammonium tetrathiomolybdate compound; or (b) at least one component of an assay system for determining serum ceruloplasmin levels.

19. (currently amended) The kit of claim 18, wherein said at least ~~a first~~ one tetraalkylammonium tetrathiomolybdate compound is disposed in a pharmaceutically acceptable composition.

20. (currently amended) The kit of claim 18, wherein said at least ~~a first~~ one tetraalkylammonium tetrathiomolybdate compound is tetrapropylammonium tetrathiomolybdate.

21. (currently amended) The kit of claim 18, wherein said kit comprises said at least ~~a first~~ one tetraalkylammonium tetrathiomolybdate compound and said ~~at least a second, distinct~~ therapeutic agent.

22. (currently amended) The kit of claim 21, wherein said ~~at least a second, distinct~~ therapeutic agent is a zinc compound or ~~at least a second, distinct~~ an anti-angiogenic agent.

23. (currently amended) The kit of claim 21, wherein said ~~at least a second, distinct~~ therapeutic agent is ~~at least a second, distinct~~ an anti-cancer agent.

24. (currently amended) The kit of claim 21, wherein said at least ~~a first~~ one tetraalkylammonium tetrathiomolybdate compound and said ~~at least a second, distinct~~ therapeutic agent are comprised within a single container.

25. (currently amended) The kit of claim 21, wherein said at least ~~a first~~ one tetraalkylammonium tetrathiomolybdate compound and said ~~at least a second, distinct~~ therapeutic agent are comprised within distinct containers.

26. (currently amended) The kit of claim 18, wherein said kit comprises said at least a ~~first~~ one tetraalkylammonium tetrathiomolybdate compound and said ~~at least one~~ component of an assay system for determining serum ceruloplasmin levels.

27. (original) The kit of claim 26, wherein said kit further comprises all components of an assay system for determining serum ceruloplasmin levels.

28-50. (canceled)